Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl): S6-9. Epub 2005 Nov 21.
Ayash-Rashkovsky M, Bentwich Z, Borkow G. TLR9 expression is related to immune activation but is impaired in individuals with chronic immune activation. Int J Biochem Cell Biol. 2005 Nov;37(11):2380-94.
Bavisotto L, Wang C, Jacobson I, et al; GS9190 Study Team. (abstract 49 ) Antiviral, pharmacokinetic and safety data for GS9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston. November 2-6, 2007.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23(8):1296-310.
Cooper C, Lawitz EJ, Ghali P, et al. (abstract LB11). Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients: results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, November 2-6, 2007.
Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003 Apr;9(4):331-8.
Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000 Apr;31(4):1014-8.
Di Bisceglie AM, Shiffman ML, Everson GT, et al. (abstract LB1) Prolonged Antiviral Therapy With Peginterferon to Prevent Complications of Advanced Liver Disease Associated With Hepatitis C: Results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 2-6, 2007.
Flisiak R, Horban A, Kierkus J, et al. (abstract 1130) The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects. 57th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. October 27-31, 2006.
Hezode C, Ferenci P, Dusheiko G, et al. (abstract 80) Prove-2: Phase II study of VX-950 (telaprevir) in combination with peginterferon with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. . 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 2-6, 2007.
Jacobson IM, Everson GT, Gordon SG, et al. (abstract 177 ) Interim analysis results from a phase II study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 2-6, 2007.
Kaita K, Yoshida E, Kumimoto D, et al. (abstract 324227) Phase II study of Celgosivir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 non-responder patients. Digestive Disease Week 2007. Washington, DC. May 19-24, 2007.
Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003 Nov 13;426(6963):186-9.
Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol. 2006 Jun;80(12):6146-54.
Le Pogarm S, Seshaadri A, Kosaka A, et al. (abstract 1298) A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment-naive patients. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 2-6, 2007.
McHutchison JG, Reddy R, Rodriguez-Torres M, et al. (abstract 61) Potent antiviral activity of the nucleoside HCV inhibitor, R7128, in prior IFN non-responders. Frontiers in Drug Development in Viral Hepatitis (HEP-DART). Lahaina, Hawaii. December 9-13, 2007.
Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother. 2005 Oct;49(10):4305-14.
Petersen ML, Wang Y, van der Laan MJ, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007 Oct 1;45(7):908-15.
Pokros P, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007 Aug;46(2):324-9 (a).
Pokros P, Nelson D, Godofsky E, et al. (abstract 67) Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (40KD), with or without ribavirin—interim analysis results of Phase 2a study. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 2-6, 2007 (b).
Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006 Jul 19;3:CD001442.
Rustgi VK, Esposito S, Hamzeh FM, et al. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther. 2008 Mar 1;27(5):433-40.
Schiff ER, Everson GT, Tsai N, et al. (abstract 1304) HCV-Specific Cellular Immunity, RNA Reductions, and Normalization of ALT in Chronic HCV Subjects after Treatment with GI-5005, a Yeast-Based Immunotherapy Targeting NS3 and Core: A Randomized, Double-blind, Placebo Controlled Phase 1b Study. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 2-6, 2007.
Sherman KE, Anderson J, Butt A, et al. ACTG A5178 Study Team. (abstract 59) Sustained Long-term Antiviral Maintenance with Pegylated Interferon in HCV/HIV-co-infected Patients: Early Viral Response and Effect on Fibrosis in Treated and Control Subjects. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 3-6, 2008.
Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006 Aug 14-28;166(15):1632-41. World Health Organization Initiative for Vaccine Research (IVR). Hepatitis C 2007. Available on-line at: www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (Accessed on March 3, 2008).
Zhou Y, Müh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem. 2007 Aug 3;282(31):22619-28.
Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus. Antimicrob Agents Chemother. 2008 Jan;52(1):110-20.